Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D2 | Q14995 | 2/20 | 0.54 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | PPM1D | O15297 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18021965 | 0.99 | NR1D2 (0.55) | NR1D2NR1D1SCN9ASSTR3OPRL1 | |
| Hydrochloric Acid SCHEMBL17982829 | 0.98 | NR1D2 (0.54) | NR1D2NR1D1SCN9ASSTR3OPRL1 | |
| SCHEMBL17982793 | 0.91 | NR1D2 (0.58) | NR1D2NR1D1SCN9ASSTR3OPRL1 | |
| Hydrochloric Acid SCHEMBL16636211 | 0.89 | NR1D2 (0.54) | NR1D2NR1D1SCN9ASSTR3OPRL1 | |
| SCHEMBL18021970 | 0.88 | NR1D2 (0.53) | NR1D2NR1D1SCN9ASSTR3OPRL1 | |
| SCHEMBL17982824 | 0.88 | NR1D2 (0.71) | NR1D2NR1D1ATMLMNA | |
| Hydrochloric Acid SCHEMBL16636258 | 0.87 | NR1D2 (0.52) | NR1D2NR1D1SCN9ASSTR3OPRL1 | |
| SCHEMBL18021950 | 0.86 | NR1D2 (0.73) | NR1D2NR1D1SSTR3ATM | |
| SCHEMBL29906510 | 0.86 | NR1D2 (0.73) | NR1D2NR1D1SSTR3ATM | |
| Hydrochloric Acid SCHEMBL16638032 | 0.85 | NR1D2 (0.71) | NR1D2NR1D1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055293-B1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FOND ST ITALIANO TECNOLOGIA (IT) | 2017-12-06 | — | — | EP | claimed |
| US-9611245-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-04-04 | — | — | US | claimed |
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2016-08-18 | — | — | US | claimed |
| EP-3055293-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | Fondazione Istituto Italiano di Tecnologia (IT) | 2016-08-17 | — | — | EP | claimed |
| WO-2015052283-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-04-16 | — | — | WO | claimed |
| US-9949968-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2018-04-24 | — | — | US | disclosed |
| EP-3055293-B1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FOND ST ITALIANO TECNOLOGIA (IT) | 2017-12-06 | — | — | EP | disclosed |
| US-20170136009-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-05-18 | — | — | US | disclosed |
| US-9611245-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-04-04 | — | — | US | disclosed |
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | NR1D1, NR1I3, BCOR | NR1D2 9/4885NR1D1 1/4885SCN9A 3850/4885 |
| US-20170136009-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | NR1D1, NR1I3, BCOR | NR1D2 9/4885NR1D1 1/4885SCN9A 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.